Peptide Comparisons
Head-to-head matchups — efficacy, dosing, side effects, and cost lined up side by side. For when the choice is down to two and you need to pick.
Bioglutide vs Retatrutide: Oral Quad vs Injectable
Bioglutide (NA-931) is an oral quadruple agonist; retatrutide an injectable triple. How the two obesity compounds actually compare in 2026.
GLP-4 vs GLP-5: Bioglutide vs VRX-0075
Bioglutide (GLP-4) adds muscle-sparing IGF-1 and has oral human data; VRX-0075 (GLP-5) adds amylin for deeper loss but is rat-only. Full comparison.
Cagri+Tirz vs Cagri+Sema: Amylin Pairing Choice
REDEFINE 1 hit 22.7% with cagrilintide + semaglutide. Cagrilintide + tirzepatide has stronger GIP. Mechanistic case, trial data, and the open question.
Cagrilintide vs Semaglutide: Different Paths
They target different receptors entirely — and combining them produces 22.7% weight loss. Mechanism, efficacy, and when to use each.
Retatrutide vs Semaglutide: Triple vs Single Agonist
Phase 2 trials reported 24.2% weight loss for retatrutide vs 14.9% for semaglutide in STEP 1 — but only one is FDA-approved. Full side-by-side.
Retatrutide vs Tirzepatide: What the Trials Show
Retatrutide hit 24% weight loss vs tirzepatide's 22.5% — but it also raises heart rate more, and the glucagon receptor is why. What the data shows.
Oral GLP-1 vs Injectable: Pills vs Shots Compared
Orforglipron and Pfizer's PF-3944 are reshaping the GLP-1 landscape — when oral pills make sense, when shots still win, and what trials show.
Semaglutide vs Tirzepatide: One Clear Winner
Tirzepatide hits two receptors, semaglutide hits one — but that's not the whole story. Head-to-head on weight loss, sides, and cost.
